Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Roila, F ^a   Herrstedt, J ^b   Aapro, M ^c   Gralla, R J ^d   Einhorn, L H ^e   Ballatori, E ^f   Bria, E ^g   Clark Snow, R A ^h   Espersen, B T ⁱ   Feyer, P ^j   Grunberg, S M ^k   Hesketh, P J ^l   Jordan, K ^m   Kris, M G ⁿ   Maranzano, E ^o   Molassiotis, A ^p   Morrow, G ^q   Olver, I ^r   Rapoport, B L ^s   Rittenberg, C ^t   Saito, M ^u   Tonato, M ^v   Warr, D ^w   more..

^a Department of Medical Oncology   (Italy)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Institut Multidisciplinaire d'Oncologie   (Switzerland)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e WALTHER CANCER INSTITUTE   (United States)

^f Medical Statistician   (Italy)

^g REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^h Lawrence Memorial Hospital   (United States)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^j Vivantes Clinic   (Germany)

^k UNIVERSITY OF VERMONT   (United States)

^l LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^m MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o S MARIA HOSPITAL   (Italy)

^p UNIVERSITY OF MANCHESTER   (United Kingdom)

^q UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^r Cancer Council Australia   (Australia)

^s Medical Oncology Centre of Rosebank   (South Africa)

^t Rittenberg Oncology Consulting   (United States)

^u JUNTENDO UNIVERSITY HOSPITAL   (Japan)

^v Umbria Regional Cancer Network   (Italy)

^w UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; AZACITIDINE; BENDAMUSTINE; CARMUSTINE; CASOPITANT; CHLORMETHINE; CISPLATIN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; EPIRUBICIN; FOSAPREPITANT; GRANISETRON; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; ONDANSETRON; OXALIPLATIN; PALONOSETRON; STREPTOZOCIN; TROPISETRON; UNINDEXED DRUG;

ANTICIPATORY NAUSEA AND VOMITING; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR THERAPY; BIBLIOGRAPHIC DATABASE; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; EUROPE; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL EXPERT; MEDICAL SOCIETY; MEDICAL SPECIALIST; MEDLINE; NAUSEA AND VOMITING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 77954319603     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq194     Document Type: Article

References (34)

1. Roila F, Hesketh PJ, Herrstedt J et al. Prevention of chemotherapy-and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-28.
2. Herrstedt J, Roila F. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2009; 20 (Suppl 4): 156-158.
3. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932-2947.
4. Hesketh PJ. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer 2001; 9: 350-354.
5. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-4119.
6. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090-3098.
7. Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy inhigh-dose cisplatin treatment. Ann Oncol 2006; 17: 1000-1006.
8. Roila F, Rolski J, Ramlau R et al. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Ann Oncol 2009; 20: 1867-1873.
9. Grunberg SM, Rolski J, Strausz J et al. Efficacy and safety of casopitant mesylate, a neurokinin-1 receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 549-558.
10. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-1449.
11. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10: 115-124.
12. Bria E, Lesser M, Raftopoulos H et al. Using two meta-analysis methods to determine whether common dose differences affect efficacy with the serotonin antagonist (5-HT) palonosetron: an individual patient data (IPD) meta-analysis and an abstracted data (AD) meta-analysis of 1947 patients entered into the 8 double-blinded randomized clinical trials (RCTs). Support Care Cancer 2009; 17: 872 (Abstr 02-007).
13. Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 1998; 16: 2937-2942.
14. Chawla SP, Grunberg SM, Gralla RJ et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 2290-2300.
15. Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs 2007; 16: 1977-1985.
16. Lasseter KC, Gambale J, Jin B et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 2007; 47: 834-840.
17. Grunberg SM, Hesketh PJ, Carides AD et al. Relationships between the incidence and control of cisplatin-induced acute vomiting and delayed vomiting: analysis of pooled data from two phase III studies of the NK-1 antagonist aprepitant. Proc ASCO 2003; 22: 2931a.
18. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23: 2822-2830.
19. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-2482.
20. Gralla R, Lichinitser M, Van DV et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-1577.
21. Yeo W, Mo FKF, Suen JJS et al. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 2009; 113: 529-535.
22. Rapoport B, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 2010; 18: 423-431.
23. Arpornwirat W, Albert I, Hansen VL et al. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer 2009; 115: 5807-5816.
24. Herrstedt J, Apornwirat W, Shaharyar A et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 2009; 27: 5363-5369.
25. Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000; 342: 1554-1559.
26. De Wit R, de Boer AC, van Linden GHM et al. Effective cross-over to granisetron after failure to ondansetron, a randomized double-blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 2001; 85: 1099-1101.
27. Passik SD, Loehrer PJ, Navari RJ et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients receiving chemotherapy: A Hoosier Oncology Group study. Proc ASCO 2002; 21: 374.
28. Choo SP, Kong KH, Lim WT et al. Electroacupuncture for refractory acute emesis caused by chemotherapy. J Altern Complement Med 2006; 12: 963-969.
29. Hesketh PJ, Younger J, Sanz-Altamira P et al. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer 2009; 17: 1065-1070.
30. Oechsle K, Muller MR, Hartmann JT et al. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT3 antagonists and dexamethasone. Onkologie 2006; 19: 557-561.
31. Paul B, Trovato JA, Thompson J et al. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 2010; 16: 45-51.
32. Roscoe JA, Morrow GR, Colagiuri B. Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer Published online August 23, 2009; PMID: 19701781.
33. Meiri E, Jhangiani H, Vredenburgh JJ et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 2007; 23: 533-543.
34. Ryan JL, Heckler C, Dakhil SR et al. Ginger for chemotherapy-related nausea in cancer patients: a URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients. J Clin Oncol 2009; 27 (Suppl): 485 (Abstr 9511).